Translating Breakthroughs in RSV Vaccine Science Into Care for Older Adults (Enduring from 23LV231)

Intended Audience: Infectious diseases specialists and their interprofessional teams of NPs, PAs, nurses and pharmacists

Decades of work have led to exciting new developments in respiratory syncytial virus (RSV) prevention, with the first-ever vaccines against RSV recently approved for use in older adults. Get ready to support implementation of these novel prevention strategies in your practice by tuning in to this enduring accredited video from IDWeek 2023, where a renowned panel of experts in RSV and vaccine science discuss:

• Impacts of RSV on the aging population and the healthcare system
• The science behind new and emerging vaccines to prevent RSV
• Real-world, evidence-based strategies to engage older adults in shared decision-making about RSV vaccination

PRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.75 contact hours (which includes 0.4 hour of pharmacology).

*PRIME® has identified, reviewed, and mitigated all relevant financial relationships that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with ineligible companies to disclose:

• Helen Chu, MD, MPH (Speaker)
  
  Advisory Board or Panel – AbbVie, Merck, Vir
  Speakers Bureau or other Promotional Education – Catalyst CME, Clinical Care Options CME, Medscape CME, Vindico CME
  The relationships reported above are related to the following therapeutic area: Infectious Disease
• Angela Branche, MD (Speaker)
  
  Advisory Board or Panel – Novavax
  Consultant – GlaxoSmithKline, Moderna
  Grants / Research Support – Cyanvac, Moderna, Novavax, Vaccine.com
  The relationships reported above are related to the following therapeutic area: Infectious Disease
• Stefan Gravenstein, MD, MPH (Speaker)
  
  Advisory Board or Panel – Genentech, GlaxoSmithKline, Janssen, Moderna, Novavax, Pfizer
  Consultant – Genentech, GlaxoSmithKline, Janssen, Merck, Moderna, Novavax, Pfizer, Reviral, Seqirus
  Grants / Research Support – Genentech, Moderna, Pfizer, Sanofi, Seqirus
  Speakers Bureau or other Promotional Education – GlaxoSmithKline, Janssen, Moderna, Pfizer, Sanofi, Seqirus
  The relationships reported above are related to the following therapeutic area: Vaccines

The following individuals have no relevant financial relationships with ineligible companies to disclose:

• Michael R Stinchon, Jr, RPh (Moderator)
• Ricardo Correa, MD, EdD, FACP, FACE, FAPCR, FACMQ (Reviewer)
• Gabriela Andonie, PharmD, BCIDP, AAHIVP (Planner)
• Lisa Wakefield, MSN, APRN, FNP-BC (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with ineligible companies to disclose.